An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

Sponsor: Nova Mentis Life Science Corp
Recruitment Status: Recruiting
First Posted: April 27, 2023

~

LUCID-201–001: A Double-Blind, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Lucid-201 in Healthy Male and Female Volunteers and Patients with Depressive Symptoms on a selective-serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI)

Funding source: FSD Pharma Australia Pty Ltd
Date registered: Apr 28, 2023
Principal investigator: Dr Philip Ryan

~

Pressing regulatory challenges for psychedelic medicine (McGuire et al.)

Published: Apr 27, 2023
Science

~

(PREPRINT) Psychedelic Concentrations of Nitrous Oxide Reduce Functional Differentiation in Frontoparietal and Somatomotor Cortical Networks (Dai et al.)

Available Online: Apr 27, 2023
bioRxiv